February 23, 2020
Brisbane, Australia-based public company ResApp, which creates smartphone apps for the diagnosis and management of respiratory diseases, announced last week that it has received firm commitments from institutional and sophisticated investors to raise $5 million.
The funds raised will be used to accelerate European commercialization and for general working capital. The placement received strong...
September 4, 2018
Top-line data from the latest trial of ResApp’s smartphone-based diagnostic algorithm for respiratory diseases suggest that the machine learning tool’s conclusions generally align with clinical diagnoses when employed for younger patients.
The double-blind, prospective Breathe-Easy pediatric study was conducted among a cohort of 585 Australian children whose ages ranged from 29 days to 12 years,...
May 9, 2017
International medical organization Doctors Without Borders (Médecins sans Frontières, or MSF) is looking to evaluate the use of an app to diagnose and manage respiratory disease in rural, low-income settings. An unofficial collaboration is already in the works with Australian digital health company ResApp, whom MSF has indicated they are interested in working with in a clinical study.